Index

AB cancer vaccine, 174t
Adulterated food products
  EPA regulation of, 37
  FDA regulation of (See Food and Drug Administration (FDA))
Advisory Committee of the Food and Commodities Act (ACWW), 90–91
Agence Française de Sécurité Sanitaire des Aliments (AFSSA), 77–78
Agreement on Sanitary and Phytosanitary Measures (SPS Agreement), 66–67
ALCESTE, 129
Allergenicity
  risk assessment, 36
  risk assessment (US), 36
  safety assessment (EU), 76–77
Animal and Plant Health Inspection Service (APHIS), 28–33, 42–43, 53–54
Animal feed
  EU regulation effects, 159–160, 161, 162t
GM foods as, 42–43
  Regulation (EC) No 1829/2003, 70–71, 71f, 73
  whole GM toxicity studies, 77–78, 83
Aprotinin, 182–183
Argentina
  acreage planted to GM crops in, 57
  ecological disasters, GM crop-induced, 102–103
  GM soybean production in, 118
  regulation, public discourse effects on, 6
Australia, 6, 57
Austria
  coexistence legislation, 63
  GMO acceptance in, 80–81
  perception of GMO as risk in, 81–82
  regulation, public discourse effects on, 6
  risk assessment in, 97–98
  safeguard clause invocation by, 62
  Aventis, 42–43, 51–52
  Aviation industry, 239, 260–261
  Avidin, 182–183
BASF, 179–180
Bayer, 179–180
Beck, U., 128
Belgium, coexistence legislation in, 63
Biological containment
  molecular mechanisms, 183–185
  pharming molecular mechanisms, 183–185, 185t, 189, 192–195
  in risk governance, 3
Biopharmaceuticals. See also Pharming
  FDA regulation of, 41–42
  production of by GM plants, 169–172, 174t
Biopharming. See Pharming
Biotechnology, benefits of, 1–2
Biro (Decree on Disclosure of Information on Disasters and Serious Accidents), 89–90
Bock, A.-K., 145
Bolivia, 57
Bounded sociotechnical experiments (BTSEs), 223–229

268
Brazil
acreage planted to GM crops in, 57, 113–114, 114n
agricultural tradition, interests in, 116–118
Biosafety Law classes, 131–132
Biosafety Laws, 119–120
Biosafety Statute (1105/2005), 124–125
competitiveness in international market, 118–119
coordination of governance in, 115–116
economic interests in biosafety statutes, 125, 125n, 126
Economy class, 130
EMBRAPA, 117–118
Federal Constitution Article 225, 123n
illegal GM crop cultivation in, 115, 118–119, 123–125
Labeling Decree, 124
labeling requirements in, 124
Landless Workers Movement – MST class, 132
media coverage in, 115, 126–129, 129t, 130f, 132t, 133
Monsanto vs. NGOs, 122, 122n, 123, 123n
moratoriums, 122–123
National Biosafety Commission (CNBS), 126
National Biosafety Technical Commission (CTNBio), 117–118, 120–121, 120n, 121n, 126
policy changes in, 115, 123–125
regulation, public discourse effects on, 6
Research class, 130–131
risk governance in generally, 120–121, 133–135
Science, Technology, and Society class, 131
social representation in, 126–133
soybean production in, 118
transgenic soybean products, NGO opposition to, 114–115, 122n, 123n
Brazilian Public Agricultural Research Corporation (EMBRAPA), 117–118
Buffer zones
economic impact of, 154–159, 245–246
evidence of need for, 18
German IP systems, regional costs of, 151–152, 152t, 153t, 154, 155t, 158t
maize crop production effects, 146t, 147, 148t
safety barriers (See Safety barriers)
Canada
acreage planted to GM crops in, 57
pharming in (See Pharming)
regulation, public discourse effects on, 6
Carnations, 62n
CaroRx™, 174t
Cartagena Protocol (Rio Declaration), 114, 114n, 122–123
Chemical industry, 260–261
Chernobyl, 240
China, 6, 57
Citizen participation. See Public participation
Clones of livestock, FDA regulation of, 43–44
Cobento, 179–180
Coexistence
buffer zones (See Buffer zones)
controversy regarding, 102–103
economic impact of, 142–144, 147t, 154–159, 161–165
in EU generally, 139–142
German IP systems, regional costs of, 151–152, 152t, 153t, 154, 155t, 158t
maize crop production economic effects, 144–146, 147, 148t
maize seed production, 149–150, 150t, 151f, 151, 164
in pharming products, 187–188
pollen flow prevention measures, 143t
Common law
governance of new technology by, 24–26
liability generally, 44–48
liability scenarios, 48–52
risk governance and, 9
Congress
on APHIS program, 30
Coordinated Framework acceptance by, 26–27, 37
EPA authority grants by,
European Union (EU). See also specific countries
acceptance of GMO, derived foods in, 78–82, 83, 94–96, 165, 206–208
acreage planted to GM crops in, 57
coexistence legislation, 63
Coordinated Framework for Regulation of Biotechnology, 26–28, 37
Directive 2001/18/EC, 60t, 62–67, 190–191
Directive 90/220/EEC authorization, 59–60, 60t, 62
ENTRANSFOOD, 73–74, 211–212
Federal Institute for Risk Assessment (BfR), 77–78
GM crop, food market in, 18
GMO authorization procedure, 58–59
GMO-free zones in, 209–210
labeling of GM foods in, 41
labeling requirements, 67–68, 71f, 72, 139–142, 210–211
liability (See Liability)
moratorium, 59–62, 66–67, 70, 93, 94, 125, 208–209
moratoriums, 59–62, 66–67, 70, 93, 94, 125, 208–209
novel foods regulation (See Novel foods regulation (EU))
pharming in (See Pharming)
policy concerns, addressing, 85–87
Regulation 396/2005, 187–188
Regulation (EC) No 1829/2003, 60t, 70–71, 71f, 73, 140, 187–188
Regulation (EC) No 1830/2003, 60t, 72, 140
regulations generally, 6, 139–142, 208–213
risk governance in generally, 8–10, 82–84, 139–142
safeguard provisions, 59–62, 64–67
safety assessment in (See Safety assessment (EU))
traceability in, 139–142, 210–211
WTO panel, 66–67
Experimental use permits (EUPs), 35
Familiarity principle, 29–30, 186–187
Federal Food Drug and Cosmetic Act, 37
Federal Institute for Risk Assessment (BfR), 77–78
Feline parvovirus vaccine, 174t
Field studies. See Coexistence; Safety science
Finland, 80–82
Flowers, 62n
Food additives, 17, 68–70
Food and Commodities Act, 90–91
Food and Consumer Product Safety authority (VWA), 105–109
Food and Drug Administration (FDA), 21, 37–44
Food industry
GMO labeling requirements, 159–161
governance of new technology in, 24–26
innovations, restrictions on, 195–196
marketing strategies, 19–20
molecular containment mechanisms, 183–185
nanotechnology application, 7
in pharming debate, 197–198, 199–200
pharming in US/Canada, 173–178
Food retailers
crop contamination and, 6–7, 41–42
elite consumers and, 18
GMO labeling requirements, 199–200
in production cycle, 17
Food safety 20, 110–111. See also Safety assessment
France
AFSSA, 77–78
coeexistence, economic effects of, 142–144
coeexistence legislation, 63
GMO acceptance in, 80–81
maize crop production economic effects, 144–146, 146t, 147, 148t
maize MON810 banning by, 64–65
maize seed production, 149–150, 150t, 151f, 151, 164
pharming in (See Pharming)
regulation, public discourse effects on, 6
risk assessment in, 97–98
safeguard clause invocation by, 62
Friends of the Earth
on APHIS, 36
on FDA consultation process, 39–40
INDEX

Gastric lipase, 174t
Gene flow. See Buffer zones; Safety barriers
Generally Recognized as Safe (GRAS), 37–38
Genetic engineering challenges in, 75 objections to, 102 products, public acceptance of, 199 risk as part of, 113 safety science in, 237
Germany acreage planted to GM crops in, 57 coexistence, economic impact of, 154–159, 162t coexistence legislation, 63 EU regulation effects, 159–160, 160f, 161, 162t GMO acceptance in, 80–81 IP systems, regional costs of, 151–152, 152t, 154, 155t, 158t maize MON810 banning by, 64–65 regulation, public discourse effects on, 6 safeguard clause invocation by, 57n, 62 Globalization, domestic governance and, 25–26 Global Reporting Initiative (GRI), 201–202, 215–223, 229–231 GM acreage in Brazil, 57, 113–114, 114n commodity crops vs., 22–23 by EU country, 57 GM crops as commodity crops, 21 as contested technology, 240 (See also Controversies generally) environmental impacts, 246 EU authorization procedure, 58–59 focus of, 202–203 hazard uncertainty regarding, 242–244 health benefits of, 96 products, public acceptance of, 199 GM crop seed contamination, prevention of, 246 liability issues, 49–50, 164 production, coexistence effects, 149–151, 164 GM food safety assessment. See Safety assessment
INDEX

Japan, 18

Krimsky, S., 205

Labeling requirements
  in Brazil, 124
  in EU, 67–68, 71f, 72, 139–142, 210–211
  substantial equivalence assumption in, 41
  in US, 40

Latvia, 63, 80–81

Learning, 223–229

Liability
  common law, 44–48
  GM crop seed, 164
    overview, 18–19
    in pharmin products, 188–189
    scenarios, 48–52
    theories, 45–47

Lithuania, 63, 80–81

Litigation. See also Liability
  class actions, 45
  future harm scenario, 48–49

Luhman, Niklas, 113, 115–116

Luxembourg, 62, 63, 80–81

Maize
  authorizations, notifications by variety, 60t
  Bt11, 60t, 70, 94
  Bt176, 59, 60t
  BtT25, 60t, 62, 64–65
  coexistence, economic effects of, 142–144
  crop production economic effects, 144–146, 146t, 147, 148t
  German IP systems, regional costs of, 151–154
  MON810, 60t, 62, 64–65
  NK603, 60t, 63
  seed production economic effects, 149–150, 150t, 151f, 151, 164

Malta, 80–81

Mandel, Gregory, 36

Marketing
  food industry strategies, 19–20
  international trade, 115, 118–119, 133–135

postmarket environmental (PMEM) monitoring, 249–250

Meristem Therapeutics, 179–180

Mexico, 57

Mining Supplement, GRI, 231–234

Misbranding, prevention of, 40

Molecular farming. See Pharming

Monoclonal antibody production, 170, 170n. See also Biopharmaceuticals; Pharming

Monsanto
  APHIS actions in regulation of, 30–31
  Directive 90/220/EEC authorisation, 59, 60t
  glyphosate-tolerant soybeans, 86, 102–103, 122–123
  GM crop, food promotion by, 16–17
  litigations involving, 52
  NGOs vs., 122, 122n, 123, 123n
  seed purchase practices, litigations by, 95, 205

MONSOY, 122–123

Multinational corporations (MNCs), biocolonialism by, 2–3, 241. See also specific corporations

Nanotechnology, 7, 23

National Biosafety Commission (CNBS), 126

National Biosafety Technical Commission (CTNBio), 117–118, 120n, 120–121, 121n, 126

National Environmental Policy Act, 30–31

National Research Council (NRC), 32

Negligence theory of liability, 46

The Netherlands
  agriculture in, 87–88
  benefit recognition in, 103–105
  Biro, 89–90
  coexistence legislation, 63
  Decree on Disclosure of Information on Disasters and Serious Accidents (Biro), 89–90
  Decree on Genetically Modified Organisms (GMO Decree), 92
  EU Directive 90/218, 92
  EU Directive 90/219,
  EU safety assessment procedures in, 91–94

© in this web service Cambridge University Press
www.cambridge.org
The Netherlands (cont.)
food safety governance principles, 105–109
GM crop introduction, 88–90
health risk concerns, 101–102
perception of GMO as risk in, 81–82
public concerns, addressing, 86
safety assessments (See Safety assessment (Netherlands))
stakeholder participation in, 104–105
sustainability/coexistence concerns, 102–103
“unnaturalness” objection, 102
New federalist movement, 25–26
NGOs (nongovernmental organizations)
adverse event data collection by, 261
on crop yield claims, 104
Monsanto vs., 122, 122n, 123, 123n
in pharming debate, 197–198
protest of GM risk assessments by, 92
role of in public debate, 83, 98, 101–102
transgenic soybean products, opposition to, 114–115, 122, 122n, 123
Nike, 221
Novel foods regulation (EU)
authorization procedure, 68
notification procedure, 60t, 68–70
overview, 67–68, 91–94
Nuclear industry, 239, 240, 241n, 253n, 260, 260n, 261
Nuisance theory, 47
Office of Science and Technology Policy (OSTP), 26
Opinion surveys
EU (See under European Union (EU))
Eurobarometer (See Eurobarometer)
GMO acceptance generally, 206–208
US (See under United States)
Organic food
as consumer preference, 18
elite consumers, 6–7, 18
proponents of, political influence by, 17
Paraguay, 57
Pesticidal crops
EPA regulation of, 33–34, 35–36
FDA regulation of, 40
objections to, 95
StarLink corn (See Star-Link corn)
Pew Foundation, 35–36
Pharma Planta, 179–180
Pharming
EU, 174t, 179–180, 186–195
EU Technology Platforms, 180, 180n
field testing, 191–192
innovation, impacts on, 195–196
molecular confinement mechanisms, 183–185, 185t, 189, 192–195
overview, 169–172, 196–200
production methods, 181n, 192–195
products, public acceptance of, 199
public debate as necessity, 196–200
risks, 180–183, 188–189
The Philippines, 57
Physical containment
molecular mechanisms, 183–185
pharming molecular mechanisms, 183–185, 185t, 189, 192–195
in risk governance, 3
Plant breeding, 189
Plant-made industrials (PMIs). See Pharming
Plant Protection Act, 28
Poland, 6, 57
Portugal, 57, 63, 80–81
Postmarket environmental (PMEM) monitoring, 249–250
Potatoes, virus-resistant, 117–118
Precautionary principle, 237
Problem definition, 227–228
Processed food products, 15, 20, 21, 50
Prodigene, 35, 178–179
Public participation. See also Global Reporting Initiative (GRI)
Brazil, 126–133
importance of, 201–202
pharming, 196–200
as unresolved issue, 213–214
Rapeseed, 60t, 62
Reagan, Ronald, 25–26
Register of Varieties, 87–88
Regulation. See also specific countries
challenges in, 10–12
public discourse effects on, 6, 241–242
system types, 57–58
INDEX

Regulation 396/2005 (EU), 187–188
Regulation (EC) No 258/97 (EU)
authorization procedure, 68
notification procedure, 60t, 68–70
overview, 67–68
Regulation (EC) No 1829/2003 (EU), 60t,
70–71, 71f, 73, 140, 187–188
Regulation (EC) No 1830/2003 (EU), 60t,
72, 140
Reporting, role of, 215–223
Responsible Care Program, 54–55
Rio Declaration (Cartagena Protocol), 114,
114n, 122–123
Risk assessment
allergenicity, 36
Coordinated Framework, 27
Dutch guidelines, 92
pharming, 180–183
public perceptions of, 96–99
Risk communication, 104–105, 106, 109,
209
Risk governance
containment in, 3
human concerns in, 54
overview, 8–10
principles of, 110–111
Rodale, J. I., 20
Romania, 57, 63
Safety assessment
historically, 248
human, organizational factors, 249,
253–256
postmarket environmental (PMEM)
monitoring, 249–250
substantial equivalence (See Substantial
equivalence)
Safety assessment (EU)
comparative analyses, 75–76, 83
generally, 71–72, 73–75, 91–94
molecular characterization, 75, 82–83
new proteins, metabolites, 76–77
whole GM food/feed toxicity studies,
77–78, 83
Safety assessment (Netherlands)
governance principles, 105–109
overview, 88, 90–91, 92
scientific advice in, 100–101
Safety barriers. See also Buffer zones
administrative, 257
concepts, applications of, 253–256, 259
defence-in-depth design, 256
evidence of need for, 18, 239
human, 258–259
organizational, 258
technological, physical, 253n, 256–257
Safety paradigms. See Safety science
Safety science
application of to GM agriculture, 236,
238, 239, 247–253, 259–263
dissemination issue, 247–248, 252–253
farmer-corporation relationship in, 237
fieldwork studies in, 238
focus of, 235–236
future directions, 259–262, 262t, 263
in genetic engineering, 237
hazard uncertainty regarding, 242–243,
243n, 244
model, 247–253
precautionary principle, 237
principles generally, 240
stewardship, stakeholder interests in,
246, 246n, 247, 260n
toxicity issue, 247–248
US vs. EU, 238
Sample v. Monsanto, 52
Séralini, G.-E., 77–78
Slovakia, 57, 63
Social control, governance as, 24–26
Social Representations theory, 127–128
Sociotechnical experiments, 223–229
South Africa, 57
Soybean
authorizations, notifications by variety,
60t
glyphosate-tolerant, 86, 102–103
herbicide-resistant, 117–118
transgenic products, NGO opposition to,
114–115, 122n
Spain
acreage planted to GM crops in, 57
GMO acceptance in, 80–81
regulation, public discourse effects on, 6
risk assessment in, 97–98
SPS Agreement (Agreement on Sanitary
and Phytosanitary Measures), 66–67
Standard Operating Procedures (SOPs),
259–260. See also Safety assessment
Strict liability theory, 46–47
Substantial equivalence
application of, 250–252
EU interpretation of, 68–70, 74, 211
FDA interpretation of, 41
in pharming products, 186–187
public concerns regarding, 99–100
Sugarbeet H7-1, 60t
Sustainability
public concerns regarding, 102–103
reporting, role of, 215–223, 261
Sweden, 63, 81–82
Syngenta
Directive 90/220/EEC authorization, 59, 60t
maize Bt11 approval, 94
Technology assessment, 197–198, 214, 219
Tolstrup, K., 145
Toxicity
as issue, 247–248
safety science on, 247–248
whole GM food/feed studies, 77–78, 83
Traceability, 139–142, 210–211. See also Labeling requirements
Transparency
APHIS, 29, 32
in EU risk governance, 209, 212–213
FDA, 39–40
GRI efforts toward, 215–223, 241–242
the Netherlands, 86–87, 88–90, 100–101
as public demand, 86–87, 201–202, 215–223
in US generally, 52–55
Trypsin, 182–183
United Kingdom
common law liability in, 44–48
Great Britain, risk governance in, 9
safeguard clause invocation by, 62
United States
acceptance of GMO, derived foods in, 206–208
acreage planted to GM crops in, 57
APHIS, 28–33, 42–43, 53–54
Congress (See Congress)
cultural influences, 19–24
Department of Agriculture, 28–32, 33, 43–44
EPA, 33–37
FDA, 21, 37–44
GM crop, food development in, 16–19
GM soybean production in, 118
governance in generally, 24–26
governance of new technology in, 24–26, 52–55
labeling requirements in, 40
liability (See Liability)
pharming in (See Pharming)
regulation, public discourse effects on, 6
risk governance in generally, 9, 10
self-regulation in, 28, 38–39
Uruguay, 57
Utilitarian values in food choices, 21–22
Vaccine-producing GM crops, 35, 174t. See also Pharming
World Trade Organization (WTO)
on EU authorization system, 66–67, 210–211
influence of on policy, 115
Worldview, 227
Zero tolerance policy, 187–188